Ease of use is definitely a very positive attribute. The fact that you can walk up to it and get in and get out is a real advantage.
Dr. H. Charles Manning
Assistant Professor of Radiology
Dr H. Charles Manning is an Assistant Professor of Radiology at Vanderbilt University, where he uses non-invasive molecular imaging to monitor disease progression and response to therapy. Manning's group, which includes both chemists and biologists, is part of the Vanderbilt University Institute of Imaging Science. The Institute houses around 100 individuals engaged in imaging science research, and about 1/3 of those researchers perform preclinical and human imaging.
Dr Manning's research interests include detection of cancer and understanding of cancer biomarkers within the context of therapeutic response. Much of his research focuses on development of cancer probes for imaging. His group primarily works with colorectal and breast cancer, and they use a variety of imaging modalities, such as MRI, PET, and SPECT.
Near-Infrared Fluorescence Technology in Cancer Diagnostics
Dr Manning's group uses their LI‑COR Pearl® Impulse Small Animal Imaging System for various optical imaging studies, including preclinical xenograft studies. "One of the larger studies that we've conducted using the Pearl utilizes a custom-labeled monoclonal-antibody probe developed in our laboratory. This agent targets TGF-beta expression. Investigators in the Vanderbilt Center for Bone Biology are using that probe to look at TGF‑beta in bone, and in and around tumors that may be in the bone, and that's been very fruitful with the Pearl. Specifically we have evaluated a number of dyes to label this antibody with, but the most successful we have used so far has been the IRDye® 800CW dye." They find that the Pearl gives them greater sensitivity and they can detect the presence of TGF-beta at lower quantities compared to other available instrumentation. They also use the Pearl system's multichannel capabilities to view dyes activated by MMP at different wavelengths.
The Pearl is pretty straightforward; you can see the data and get right at it.
Dr Manning is impressed with how easy the Pearl is to use. "Ease of use is definitely a very positive attribute. The fact that you can walk up to it and get in and get out is a real advantage. Also the ease of processing the data is something that we hear a lot about, and the visual impressions the images make. The Pearl is pretty straightforward; you can see the data and get right at it." Manning's group has also used several of LI-COR's optical probes and IRDye fluorophores. "We always offer the LI‑COR dyes because we like their chemistry and the spectroscopy; they tend to be our go-to dyes."
We thank Dr Manning for his contributions to optical imaging and cancer research, and we are proud to consider him a Pearl Expert.
For more information about Dr. Manning's work, visit Vanderbilt University Profile.
Publications resulting from work on the Odyssey
- Molecular Imaging of Therapeutic Response to Epidermal Growth Factor Receptor Blockade in Colorectal Cancer. H. CharlesManning,1,2,3,7,8 Nipun B.Merchant,4 A. Coe Foutch,9 John M. Virostko,1,2 Shelby K. Wyatt,1,2 Chirayu Shah,1,2 Eliot T.McKinley,1,8 Jingping Xie,1Nathan J.Mutic,1,7 M. Kay Washington,5 Bonnie LaFleur,6 Mohammed Noor Tantawy,1,2 Todd E. Peterson,1,2,7 M. Sib Ansari,2 Ronald M. Baldwin,1,2 Mace L. Rothenberg,11Darryl J. Bornhop,9 John C. Gore,1,2,7,8 and Robert J. Coffey10,11,12
- Imaging Biomarkers Predict Response toAnti-HER2 (ErbB2) Therapy in Preclinical Models of Breast Cancer. Chirayu Shah,1,2 Todd W. Miller,3 Shelby K.Wyatt,1,2 EliotT.McKinley,1,4Maria Graciela Olivares,5 Violeta Sanchez,3 Donald D. Nolting,1Jason R. Buck,1,2 Ping Zhao,1M. Sib Ansari,1,2 Ronald M. Baldwin,1,2 John C. Gore,1,2,4,6,7,10,11Rachel Schiff,13,14,15 Carlos L. Arteaga,3,8,10,12 and H. CharlesManning1,2,4,9,10,11,12
- Inhibition of mTOR is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Todd W. Miller, James T. Forbes, Chirayu Shah, Shelby K. Wyatt, H. Charles Manning, Maria G. Olivares, Violeta Sanchez, Teresa C. Dugger, Nara de Matos Granja, Archana Narasanna, Rebecca S. Cook, J. Phillip Kennedy, Craig W. Lindsley, and Carlos L. Arteaga. Clin Cancer Res. 2009 Dec 1;15(23):7266-76.
- A molecular imaging paradigm to rapidly profile response to angiogenesis-directed therapy in small animals. Virostko JM, Xie J, Hallahan DE, Arteaga CL, Gore JC, Manning HC. Mol Imaging Biol 2009;11(3): 204-12. PMCID: PMC2677126
- Dr. Geir Bjørkøy
University College of Sør-Trøndelag and CEMIR Centre of Excellence, NTNU
- Dr. Wendy Bollag
Georgia Regents University, Charlie Norwood VA Medical Center
- Dr. Jeremy Chambers
Florida International University, Miami, FL
- Dr. Paul Digard
University of Cambridge, UK
- Dr. Jane Gray
Cancer Research Institute, Cambridge, UK
- Manuela Gustafsson
Karolinska Institute's Department of Laboratory Medicine
- Dr. Oliver Hantschel
- Dr. Stefan Hüttelmaier
Martin Luther University
- Dr. Jelena Janjic
- Dr. Andrea Kasinski
- Dr. Sue Katz
Rogers State University
- Dr. Lisa Keyes
University of Florida College of Medicine
- Dr. Stanislav Kholmanskikh
Weill Cornell Medical College
- Dr. Patrick Kiely
University College Cork, Ireland
- Dr. Andreas von Knethen
Johann Wolfgang Goethe-University
- Dr. Michael Lee
University of Massachusetts Medical School
- Dr. Robert Lewis
University of Nebraska
- Dr. H. Charles Manning
- Dr. Debra Martin
Saint Mary's University of Minnesota
- Dr. Kevin Morano
The University of Texas Graduate School of Biomedical Sciences at Houston
- Dr. Rick Page
Miami University in Oxford, OH
- Dr. Nicolai Peschel
Universität Würzburg Department of Neurobiology & Genetics
- Dr. Wendy Picking
Oklahoma State University
- Dr. Martin Pomper
Johns Hopkins Medical School
- Dr. Vikash Reebye
Imperial College London, UK
- Dr. Rosemary Schuh
University of Maryland School of Medicine